Don Dizon, MD, on Improving Treatment Strategies for Transgender Patients With Cancer


Don Dizon, MD, FACP, FASCO, discusses the need to improve treatment strategies for transgender patients with cancer.

In an interview with CancerNetwork®, Don Dizon, MD, FACP, FASCO, director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, highlighted that more research needs to be done to determine whether it is safe for transgender patients to continue receiving gender-affirming therapy while being treated for cancer. In particular, patients with endocrine-responsive tumors may be an area of concern, Dizon stated.


[In terms of treatment guidance], parts of it are fairly clearer than others—for example, chemotherapy, which doesn't depend on an endocrine access. It is used in women with cancer, and it's used in situations [for] men with cancer; these are [factors] that don't or shouldn't impact if someone's on gender-affirming hormone therapy; however, it's still important to note that. The bigger area of concern is for those who have those endocrine-responsive tumors. What do you do with the gender-affirming therapy after they've been diagnosed with that hormone-responsive tumor? [For] a woman coming in on combined hormone therapy—estrogen and progesterone—with breast cancer, we are going to recommend she stop hormone therapy. Do you apply that same standard to men or to transgender women on gender-affirming therapy? No one really knows. But what we do have is data from population studies in Europe, for example, that show people on gender-assigned hormone therapies don't seem to have an increased risk of cancers on those therapies.

What we need to do is collect the data. At its most basic, we need to select what types of gender-affirming therapy transgender people are on and the duration. Then in terms of what to do with our therapies beyond that, I think we need to [determine] how they are doing on those treatments. I am loath to say that they should be recommended to stop without any data at all saying their survival is negatively impacted. It's important to say that, because you're asking people to choose [between] life with the threat of cancer coming back, or life with a lower threat of cancer coming back, but as the gender they don't see themselves as. That's a huge thing.

Related Videos
In the October edition of Snap Recap, we review the latest FDA news and the vote from the last ODAC meeting.
In this September edition of Snap Recap, we share our highlights from Prostate Cancer Awareness Month, news in the breast cancer space, and the latest FDA updates.
Implementing tax benefits for manufacturers who produce chemotherapy drugs may be one solution to increase drug production in the United States, according to Lucio N. Gordan, MD.
Lucio N. Gordan, MD, describes how his practice deals with increasing costs of limited chemotherapy agents to ensure that patients with cancer continue to receive treatment.
Lucio N. Gordan, MD, also discusses how increasing domestic manufacturing of chemotherapy may help in alleviating the ongoing shortages of carboplatin and cisplatin in the United States.
Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, believes that national legislation can help to resolve the United States’ current dearth of cisplatin, as well as prevent future problems.
Using an AUC of 5 instead of an AUC of 6 can help to conserve cisplatin among patients with cancer, Kirollos Hanna, PharmD, BCPS, BCOP, FACCC says.
While there is a cisplatin shortage in the United States, the FDA has approved the importation of select chemotherapy drugs from China to help mitigate the scarcity of the agents.
Recommendations penned by the American Society of Clinical Oncology and Society for Gynecologic Oncology may be critical in managing the ongoing chemotherapy shortage, according to Michael Ganio, PharmD, MS, BCPS, FASHP.
Related Content